Soleno Therapeutics Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Soleno Therapeutics Inc 公司

Soleno Therapeutics, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於開發和商業化用於治療罕見疾病的新型療法。其主要候選藥物二氮嗪膽鹼緩釋片 (DCCR) 是一種緩釋片，是一種用於治療普拉德-威利綜合徵 (PWS) 的每日一次口服藥，最近完成了其第 3 階段開發計劃。DCCR 是一種有效的 ATP 敏感鉀 (KATP) 通道激活劑。DCCR 片劑含有活性成分二氮嗪膽鹼，二氮嗪是一種苯並噻二嗪類藥物的膽鹼鹽。DCCR 的作用模式是針對大腦、胰腺和脂肪組織，有可能影響 PWS 等複雜疾病，以減少食慾、減少食物尋求、提高飽腹感、改善胰島素和瘦素抵抗並減少體脂。該公司在美國和歐盟擁有 PWS 中 DCCR 的快速通道稱號以及該藥物的孤兒藥稱號。

公司簡介

公司代碼SLNO

公司名稱Soleno Therapeutics Inc

上市日期Oct 23, 2014

成立日期1999

CEODr. Anish Bhatnagar, M.D.

員工數量92

證券類型Ordinary Share

年結日Oct 23

公司地址100 Marine Parkway, Suite 400

城市REDWOOD CITY

上市交易所NASDAQ Capital Market Consolidated

國家United States of America

郵編94065

電話16502138444

網址https://soleno.life/

公司代碼SLNO

上市日期Oct 23, 2014

成立日期1999

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. James H. (Jim) Mackaness

Chief Financial Officer

90.68K

+32.66%

Dr. Michael Huang, M.D.

Senior Vice President - Clinical Development

36.82K

-11.07%

Ms. Kristen Yen

Senior Vice President - Global Clinical Operations and Patient Advocacy

28.14K

-66.09%

Ms. Dawn Carter Bir

Independent Director

16.99K

+30.70%

Mr. William G. (Bill) Harris

Independent Director

12.89K

+44.84%

Dr. Birgitte Volck, M.D., Ph.D.

Independent Director

11.04K

+56.65%

Dr. Andrew Sinclair, Ph.D.

Independent Director

10.49K

+61.40%

Ms. Patricia C. Hirano

Vice President - Regulatory Affairs

6.81K

-36.00%

Dr. Anish Bhatnagar, M.D.

Chairman of the Board, Chief Executive Officer

--

Ms. Meredith Manning

Chief Commercial Officer

--

名稱

名稱/職務

職務

持股

持股變動

Mr. James H. (Jim) Mackaness

Chief Financial Officer

90.68K

+32.66%

Dr. Michael Huang, M.D.

Senior Vice President - Clinical Development

36.82K

-11.07%

Ms. Kristen Yen

Senior Vice President - Global Clinical Operations and Patient Advocacy

28.14K

-66.09%

Ms. Dawn Carter Bir

Independent Director

16.99K

+30.70%

Mr. William G. (Bill) Harris

Independent Director

12.89K

+44.84%

Dr. Birgitte Volck, M.D., Ph.D.

Independent Director

11.04K

+56.65%

收入明細

暫無數據

暫無數據

業務

地區

暫無數據

股東統計

更新時間: 5月17日週六

持股股東

股東類型

持股股東

佔比

Janus Henderson Investors

10.20%

Vivo Capital, LLC

8.85%

Adage Capital Management, L.P.

8.72%

Avoro Capital Advisors LLC

5.01%

T. Rowe Price Associates, Inc.

4.70%

Other

62.53%

持股股東

佔比

Janus Henderson Investors

10.20%

Vivo Capital, LLC

8.85%

Adage Capital Management, L.P.

8.72%

Avoro Capital Advisors LLC

5.01%

T. Rowe Price Associates, Inc.

4.70%

Other

62.53%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

33.33%

Hedge Fund

31.65%

Investment Advisor

26.64%

Venture Capital

12.54%

Private Equity

4.02%

Research Firm

2.73%

Individual Investor

1.92%

Bank and Trust

0.53%

Pension Fund

0.18%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

375

57.23M

113.56%

+142.75K

2025Q1

373

57.15M

113.59%

-442.82K

2024Q4

313

53.26M

117.76%

+3.04M

2024Q3

277

49.14M

121.09%

-377.00K

2024Q2

234

44.76M

117.95%

+4.14M

2024Q1

189

36.54M

114.10%

-1.05M

2023Q4

146

32.09M

102.81%

+3.37M

2023Q3

107

21.08M

166.08%

+14.34M

2023Q2

87

5.70M

63.31%

-1.46M

2023Q1

121

4.63M

57.04%

-249.13K

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

Janus Henderson Investors

5.14M

10.2%

-47.37K

-0.91%

Mar 31, 2025

Vivo Capital, LLC

4.46M

8.85%

-1.83M

-29.14%

Mar 31, 2025

Adage Capital Management, L.P.

4.39M

8.72%

+1.62M

+58.24%

Mar 31, 2025

Avoro Capital Advisors LLC

2.52M

5.01%

--

Mar 31, 2025

T. Rowe Price Associates, Inc.

2.37M

4.7%

+768.45K

+48.07%

Mar 31, 2025

Fidelity Management & Research Company LLC

2.12M

4.21%

+1.36M

+179.00%

Mar 31, 2025

The Vanguard Group, Inc.

1.86M

3.69%

-18.21K

-0.97%

Mar 31, 2025

Nantahala Capital Management, LLC

1.76M

3.49%

-2.17M

-55.28%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

1.72M

3.4%

-105.47K

-5.79%

Mar 31, 2025

Citadel Advisors LLC

1.58M

3.13%

+603.63K

+62.08%

Mar 31, 2025

持股ETF

更新時間: 7月6日週日

機構名稱

佔比

Harbor Health Care ETF

2.39%

Invesco Dorsey Wright SmallCap Momentum ETF

2.19%

SPDR S&P Biotech ETF

1.04%

Virtus LifeSci Biotech Clinical Trials ETF

0.98%

Direxion Daily S&P Biotech Bull 3X Shares

0.5%

JPMorgan Healthcare Leaders ETF

0.44%

First Trust Multi-Manager Small Cap Opportunities ETF

0.3%

Fidelity Fundamental Small-Mid Cap ETF

0.21%

Optimize Strategy Index ETF

0.19%

BNY Mellon US Small Cap Core Equity ETF

0.15%

Harbor Health Care ETF

佔比2.39%

Invesco Dorsey Wright SmallCap Momentum ETF

佔比2.19%

SPDR S&P Biotech ETF

佔比1.04%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.98%

Direxion Daily S&P Biotech Bull 3X Shares

佔比0.5%

JPMorgan Healthcare Leaders ETF

佔比0.44%

First Trust Multi-Manager Small Cap Opportunities ETF

佔比0.3%

Fidelity Fundamental Small-Mid Cap ETF

佔比0.21%

Optimize Strategy Index ETF

佔比0.19%

BNY Mellon US Small Cap Core Equity ETF

佔比0.15%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

Aug 25, 2022

Merger

15<1

Aug 25, 2022

Merger

15<1

Aug 25, 2022

Merger

15<1

Aug 25, 2022

Merger

15<1

公告日期

類型

比率

Aug 25, 2022

Merger

15<1

Aug 25, 2022

Merger

15<1

Aug 25, 2022

Merger

15<1

Aug 25, 2022

Merger

15<1

Soleno Therapeutics Inc

80.320USD

Soleno Therapeutics Inc

80.320

概覽

公司

財務